Plasma kallikrein inhibitors in cardiovascular disease: an innovative therapeutic approach
D Kolte, Z Shariat-Madar - Cardiology in Review, 2016 - journals.lww.com
Plasma prekallikrein is the liver-derived precursor of the trypsin-like serine protease plasma
kallikrein, and circulates in plasma bound to high molecular weight kininogen. Plasma …
kallikrein, and circulates in plasma bound to high molecular weight kininogen. Plasma …
Plasma kallikrein: the bradykinin-producing enzyme
J Björkqvist, A Jämsä, T Renné - Thrombosis and haemostasis, 2013 - thieme-connect.com
Plasma prekallikrein is the liver-derived precursor of the trypsin-like serine protease plasma
kallikrein (PK) and circulates in plasma bound to high molecular weight kininogen. The …
kallikrein (PK) and circulates in plasma bound to high molecular weight kininogen. The …
Plasma kallikrein: novel functions for an old protease
T Renné, A Gruber - Thrombosis and haemostasis, 2012 - thieme-connect.com
Plasma kallikrein (PK) is a plasma protease that drives procoagulant-and proinflammatory
reactions via the intrinsic pathway of coagulation and the kallikrein-kinin system …
reactions via the intrinsic pathway of coagulation and the kallikrein-kinin system …
Human plasma kallikrein: roles in coagulation, fibrinolysis, inflammation pathways, and beyond
Human plasma kallikrein (PKa) is obtained by activating its precursor, prekallikrein (PK),
historically named the Fletcher factor. Human PKa and tissue kallikreins are serine …
historically named the Fletcher factor. Human PKa and tissue kallikreins are serine …
Role of plasma kallikrein in diabetes and metabolism
EP Feener, Q Zhou, W Fickweiler - Thrombosis and …, 2013 - thieme-connect.com
Plasma kallikrein (PK) is a serine protease generated from plasma prekallikrein, an
abundant circulating zymogen expressed by the Klkb1 gene. The physiological actions of …
abundant circulating zymogen expressed by the Klkb1 gene. The physiological actions of …
Human tissue kallikrein: a new bullet for the treatment of ischemia
C Emanueli, P Madeddu - Current Pharmaceutical Design, 2003 - ingentaconnect.com
Recently, therapeutic angiogenesis has been proposed as an alternative for the treatment of
ischemic diseases unresponsive to conventional therapy. This strategy is based on the …
ischemic diseases unresponsive to conventional therapy. This strategy is based on the …
Small molecule inhibitors of plasma kallikrein
WB Young, R Rai, WD Shrader… - Bioorganic & medicinal …, 2006 - Elsevier
Plasma kallikrein is a serine protease that is involved in pathways of inflammation,
complement fixation, coagulation, and fibrinolysis. Herein, we describe the SAR and …
complement fixation, coagulation, and fibrinolysis. Herein, we describe the SAR and …
Plasma Kallikrein as a forgotten clotting factor
KJ Kearney, HMH Spronk, J Emsley… - … in Thrombosis and …, 2023 - thieme-connect.com
For decades, it was considered that plasma kallikrein's (PKa) sole function within the
coagulation cascade is the activation of factor (F) XII. Until recently, the two key known …
coagulation cascade is the activation of factor (F) XII. Until recently, the two key known …
Aminopyridine derivatives as plasma kallikrein inhibitors
T Brandl, S Flohr, C Markert, K Namoto… - US Patent App. 14 …, 2014 - Google Patents
0002 Plasmakallikrein (PK) is the activated form of the trypsin-like serine protease plasma-
prokallikrein and is mainly expressed by hepatocytes in the liver. Activation of plasma …
prokallikrein and is mainly expressed by hepatocytes in the liver. Activation of plasma …
Kallikrein activates prothrombin
TW Stief - Clinical and Applied Thrombosis/Hemostasis, 2008 - journals.sagepub.com
Kallikrein is a multitalented enzyme in hemostasis and inflammation. Normally, kallikrein is
formed in intrinsic hemostasis and activates factor XII. A total of 10 µL of 0 to 100 µg/mL …
formed in intrinsic hemostasis and activates factor XII. A total of 10 µL of 0 to 100 µg/mL …